Sign in
Taking people in South KoreaNo phase

Reviews records of adults with colitis or Crohn's treated with vedolizumab under the skin

Reviews records of Korean adults with colitis or Crohn's given vedolizumab injections.

Key facts

Who runs it
Takeda
Where
Goyang-si, South KoreaSee the site
Trial code
Registry title
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Status
Recruiting
People taking part
600 people, planned
Started
25 Sept 2023
Expected to end
30 Nov 2027
Type of study
Observational
Record updated
6 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in South Korea with moderate to severe ulcerative colitis or Crohn's disease who are treated with vedolizumab SC. It reviews their medical files only.

Age
18 years and older
Sex
All
Disease stage
Moderately to severely active ulcerative colitis or Crohn's disease
Earlier treatment
Inadequate response, lost response or side effects with conventional therapy or a TNF-α antagonist. Also, signs of benefit after at least 2 vedolizumab infusions into a vein.

Main reasons for not taking part

  • Allergic reaction to vedolizumab or its other ingredients
  • Active severe infection such as tuberculosis, cytomegalovirus, sepsis, listeriosis or PML
  • Vedolizumab SC not allowed according to the product label

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • With moderately to severely active UC or CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist
  • With evidence of therapeutic benefit after at least 2 vedolizumab intravenous infusions

Who cannot take part

  • With hypersensitivity such as dyspnea, bronchospasm, urticaria, flushing and increased heart rate to the vedolizumab substance or to any of its excipients
  • With active severe infections such as tuberculosis, cytomegalovirus, sepsis, listeriosis and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML)
  • For whom vedolizumab SC is contraindicated as per product label

Where in South Korea

  • Donggguk University Ilsan HospitalGoyang-si, South KoreaContact: Yoon-Jung Lim, Prof. (principal investigator)Taking people

About the trial

What the trial wants to find out

The main aim of the study is to observe adult participants in South Korea that are being treated with vedolizumab injected just under the skin (subcutaneous or SC) to treat ulcerative colitis (UC) or Crohn's disease (CD) who have had an in-adequate response with, lost response to, or had too many side effects in response to either conventional therapy or a Tumor Necrosis Factor-alpha (TNF-α) antagonist. This study will observe the side effects and potential benefit to UC and CD participants related to vedolizumab SC treatment with data collection from medical files. There is no treatment involved in this study, this is only an observational review of current collected data relating to adults in South Korea with UC or CD treated with vedolizumab SC.

The group in the trial

  • Participants With UC or CD

    Participants diagnosed with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist and have initiated treatment with vedolizumab in a routine clinical practical setting in South Korea, will be observed prospectively for 52 weeks.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Post-Marketing Surveillance (Usage Results Study) of Vedolizumab Subcutaneous Injection in Patients With Ulcerative Colitis or Crohn's Disease in South Korea
Plain-language title
Reviews records of adults with colitis or Crohn's treated with vedolizumab under the skinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 October 2025